Ayala Pharmaceuticals (NASDAQ:ADXS) Coverage Initiated by Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report released on Friday. The brokerage set a “sell” rating on the stock.

Ayala Pharmaceuticals Trading Up 1.7 %

Shares of NASDAQ ADXS opened at $0.03 on Friday. The firm’s 50-day moving average price is $0.03 and its 200-day moving average price is $0.03. The stock has a market capitalization of $1.28 million, a price-to-earnings ratio of 0.00 and a beta of 1.63. Ayala Pharmaceuticals has a 12-month low of $0.00 and a 12-month high of $0.98.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.